Vascular Dysfunction in Preeclampsia

Microcirculation

Volumn 21, Issue 1, 2014, Pages 4-14

  Brennan, Lesley J ^a,b   Morton, Jude S ^a,b   Davidge, Sandra T ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Women and Children's Health Research Institute and the Cardiovascular Research Centre   (Canada)

Author keywords

Circulating factors; Endothelial dysfunction; Placental ischemia; Preeclampsia

Indexed keywords

ANGIOGENIC FACTOR;

ARTICLE; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PREECLAMPSIA; PRIORITY JOURNAL; REPRODUCTION; SYSTEMIC CIRCULATION; VASCULAR DISEASE; VASCULAR RESISTANCE; VASCULARIZATION;

CIRCULATING FACTORS; ENDOTHELIAL DYSFUNCTION; PLACENTAL ISCHEMIA; PREECLAMPSIA;

ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; OXIDATIVE STRESS; PLACENTATION; PRE-ECLAMPSIA; PREGNANCY; VASCULAR DISEASES; VASCULAR RESISTANCE;

EID: 84891619289     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/micc.12079     Document Type: Article

References (156)

1. Abdalvand A, Morton JS, Bourque SL, Quon AL, Davidge ST. Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow. Hypertension 61: 488-493, 2013.
2. Agatisa PK, Ness RB, Roberts JM, Costantino JP, Kuller LH, McLaughlin MK. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol 286: H1389-H1393, 2004.
3. Aggarwal PK, Chandel N, Jain V, Jha V. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens 26: 236-241, 2012.
4. Ahn H, Park J, Gilman-Sachs A, Kwak-Kim J. Immunologic characteristics of preeclampsia, a comprehensive review. Am J Reprod Immunol 65: 377-394, 2011.
5. Anderson CM, Lopez F, Zhang H-Y, Pavlish K, Benoit JN. Reduced uteroplacental perfusion alters uterine arcuate artery function in the pregnant Sprague-Dawley rat. Biol Reprod 72: 762-766, 2005.
6. Anderson CM, Lopez F, Zhang H-Y, Shirasawa Y, Pavlish K, Benoit JN. Mesenteric vascular responsiveness in a rat model of pregnancy-induced hypertension. Exp Biol Med 231: 1398-1402, 2006.
7. Anim-Nyame N, Sooranna SR, Johnson MR, Gamble J, Steer PJ. Resting peripheral blood flow in normal pregnancy and in pre-eclampsia. Clin Sci 99: 505-510, 2000.
8. Anim-Nyame N, Sooranna SR, Johnson MR, Gamble J, Steer PJ. A longitudinal study of resting peripheral blood flow in normal pregnancy and pregnancies complicated by chronic hypertension and pre-eclampsia. Cardiovasc Res 50: 603-609, 2001.
9. Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, Parthasarathy S, Petros JA, Lambeth JD. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci USA 98: 5550-5555, 2001.
10. Ashworth JR, Warren AY, Baker PN, Johnson IR. Loss of endothelium-dependent relaxation in myometrial resistance arteries in pre-eclampsia. BJOG 104: 1152-1158, 1997.
11. Benian A, Madazl R, Aksu F, Uzun H, Aydn S. Plasma and placental levels of interleukin-10, transforming growth factor-β1, and epithelial-cadherin in preeclampsia. Obstet Gynecol 100: 327-331, 2002.
12. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3: 211-220, 1992.
13. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human eins in vivo. Circulation 96: 3042-3047, 1997.
14. Bobst SM, Day M-C, Gilstrap LC, Xia Y, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am J Hypertens 18: 330-336, 2005.
15. Borzychowski AM, Sargent IL, Redman CWG. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 11: 309-316, 2006.
16. Buemi M, Allegra A, D'Anna R, Coppolino G, Crascì E, Giordano D, Loddo S, Cucinotta M, Musolino C, Teti D. Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hypertension. Am J Obstet Gynecol 196: 68.e1-68.e6, 2007.
17. Bussen S, Sütterlin M, Steck T. Plasma endothelin and big endothelin levels in women with severe preeclampsia or HELLP-syndrome. Arch Gynecol Obstet 262: 113-119, 1999.
18. Cao Y, Chen H, Zhou L, Chiang M-K, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, Flanagan JG, Tsang ML-S. Heterodimers of placenta growth factor/vascular endothelial growth factor: endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 271: 3154-3162, 1996.
19. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439, 1996.
20. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA 285: 1607-1612, 2001.
21. Chavarría ME, Lara-González L, González-Gleason A, García-Paleta Y, Vital-Reyes VS, Reyes A. Prostacyclin/thromboxane early changes in pregnancies that are complicated by preeclampsia. Am J Obstet Gynecol 188: 986-992, 2003.
22. Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, Massagué J, Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
23. Chesley LC. Vascular reactivity in normal and toxemic pregnancy. Clin Obstet Gynecol 9: 871-881, 1966.
24. Clark DE, Smith SK, Licence D, Evans AL, Charnock-Jones DS. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol 159: 459-467, 1998.
25. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi B-Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271: 736-741, 1996.
26. Collins PD, Connolly DT, Williams TJ. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br J Pharmacol 109: 195-199, 1993.
27. Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL, Leimgruber R, Feder J. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 264: 20017-20024, 1989.
28. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 40: 102-111, 1998.
29. Cook-Mills JM, Deem TL. Active participation of endothelial cells in inflammation. J Leukoc Biol 77: 487-495, 2005.
30. Craici I, Wagner S, Garovic VD. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis 2: 249-259, 2008.
31. Crews JK, Herrington JN, Granger JP, Khalil RA. Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. Hypertension 35: 367-372, 2000.
32. Crocker IP, Kenny LC, Thornton WA, Szabo C, Baker PN. Excessive stimulation of poly(ADP-ribosyl)ation contributes to endothelial dysfunction in pre-eclampsia. Br J Pharmacol 144: 772-780, 2005.
33. Daniel Y, Kupferminc MJ, Baram A, Jaffa AJ, Fait G, Wolman I, Lessing JB. Plasma interleukin-12 is elevated in patients with preeclampsia. Am J Reprod Immunol 39: 376-380, 1998.
34. Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, Park J-K, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, Luft FC. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 107: 1632-1639, 2003.
35. Dekker GA, Kraayenbrink AA, Zeeman GG, van Kamp GJ. Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 40: 215-220, 1991.
36. Demir R, Kayisli UA, Seval Y, Celik-Ozenci C, Korgun ET, Demir-Weusten AY, Huppertz B. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta 25: 560-572, 2004.
37. Deng L, Bremme K, Hansson LO, Blomback M. Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia. Obstet Gynecol 84: 941-945, 1994.
38. Dennis AT, Castro J, Carr C, Simmons S, Permezel M, Royse C. Haemodynamics in women with untreated pre-eclampsia. Anaesthesia 67: 1105-1118, 2012.
39. Deroanne CF, Hajitou A, Calberg-Bacq C-M, Nusgens BV, Lapière CM. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 57: 5590-5597, 1997.
40. Duley L. The global Impact of pre-eclampsia and eclampsia. Semin Perinatol 33: 130-137, 2009.
41. Dumont A, Hehner SP, Hofmann TG, Ueffing M, Dröge W, Schmitz ML. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kappaB. Oncogene 18: 747-757, 1999.
42. English FA, McCarthy FP, McSweeney CL, Quon AL, Morton JS, Sawamura T, Davidge ST, Kenny LC. Inhibition of lectin-like oxidized low-density lipoprotein-1 receptor protects against plasma-mediated vascular dysfunction associated with pre-eclampsia. Am J Hypertens 26: 279-286, 2013.
43. Evans PW, Wheeler T, Anthony FW, Osmond C. A longitudinal study of maternal serum vascular endothelial growth factor in early pregnancy. Hum Reprod 13: 1057-1062, 1998.
44. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
45. Gant NF, Chand S, Worley RJ, Whalley PJ, Crosby UD, Macdonald PC. A clinical test useful for predicting the development of acute hypertension in pregnancy. Obstet Gynecol Surv 30: 170-171, 1975.
46. Gao X, Belmadani S, Picchi A, Xu X, Potter BJ, Tewari-Singh N, Capobianco S, Chilian WM, Zhang C. Tumor necrosis factor-α induces endothelial dysfunction in Leprdb mice. Circulation 115: 245-254, 2007.
47. Garovic VD, Hayman SR. Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol 3: 613-622, 2007.
48. Giardina JB, Cockrell KL, Granger JP, Khalil RA. Low-salt diet enhances vascular reactivity and Ca2+ entry in pregnant rats with normal and reduced uterine perfusion pressure. Hypertension 39: 368-374, 2002.
49. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble Fms-like tyrosine kinase-1 expression. Hypertension 50: 1142-1147, 2007.
50. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 294: H541-H550, 2008.
51. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension. Hypertension 55: 380-385, 2010.
52. Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC. Tumor necrosis factor-α reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Circ Physiol 293: H1115-H1121, 2007.
53. Haeger M, Linander M, Norder-Hansson B, Tylman M, Bengtsson A. Complement, neutrophil, and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 79: 19-26, 1992.
54. Hajjar KA, Hajjar DP, Silverstein RL, Nachman RL. Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells. J Exp Med 166: 235-245, 1987.
55. Hamai Y, Fujii T, Yamashita T, Nishina H, Kozuma S, Mikami Y, Taketani Y. Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-α levels before the clinical manifestations of preeclampsia. Am J Reprod Immunol 38: 89-93, 1997.
56. Hayman R, Warren A, Brockelsby J, Johnson I, Baker P. Plasma from women with pre-eclampsia induces an in vitro alteration in the endothelium-dependent behaviour of myometrial resistance arteries. BJOG: An International Journal of Obstetrics & Gynaecology 107: 108-115, 2000.
57. Hildeman DA, Mitchell T, Teague TK, Henson P, Day BJ, Kappler J, Marrack PC. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 10: 735-744, 1999.
58. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol Heart Circ Physiol 274: H1054-H1058, 1998.
59. Hubel CA, Sipos PI, Crocker IP. Endothelial progenitor cells: their potential role in pregnancy and preeclampsia. Pregnancy Hypertension 1: 48-58, 2011.
60. Hubel CA, Wallukat G, Wolf M, Herse F, Rajakumar A, Roberts JM, Markovic N, Thadhani R, Luft FC, Dechend R. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension 49: 612-617, 2007.
61. Jung Y, Liu W, Reinmuth N, Ahmad S, Fan F, Gallick G, Ellis L. Vascular endothelial growth factor is upregulated by interleukin-1β in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis 4: 155-162, 2001.
62. Kenny LC, Baker PN, Kendall DA, Randall MD, Dunn WR. Differential mechanisms of endothelium-dependent vasodilator responses in human myometrial small arteries in normal pregnancy and pre-eclampsia. Clin Sci 103: 67-73, 2002.
63. Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 29: 464-470, 2009.
64. Knight J. Free radicals, antioxidants, and the immune system. Ann Clin Lab Sci 30: 145-158, 2000.
65. Knock GA, Poston L. Bradykinin-mediated relaxation of isolated maternal resistance arteries in normal pregnancy and preeclampsia. Am J Obstet Gynecol 175: 1668-1674, 1996.
66. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88: 2348-2351, 2003.
67. Konijnenberg A, Stokkers EW, van der Post JAM, Schaapb MCL, Boer K, Bleker OP, Sturk A. Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol 176: 461-469, 1997.
68. LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, Wallukat G, Wenzel K, Cockrell K, Martin JN, Ryan MJ, Dechend R. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension 54: 905-909, 2009.
69. LaMarca B, Wallace K, Herse F, Wallukat G, Martin JN, Weimer A, Dechend R. Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes. Hypertension 57: 865-871, 2011.
70. LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor α in pregnant rats. Hypertension 52: 1168-1172, 2008.
71. Lees MM, Taylor SH, Scott DB, Kerr MG. A study of cardiac output at rest throughout pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology 74: 319-328, 1967.
72. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992-1005, 2006.
73. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683, 2004.
74. Li J, LaMarca B, Reckelhoff JF. A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model. Am J Physiol Heart Circ Physiol 303: H1-H8, 2012.
75. Li J, Stouffs M, Serrander L, Banfi B, Bettiol E, Charnay Y, Steger K, Krause K-H, Jaconi ME. The NADPH oxidase NOX4 drives cardiac differentiation: role in regulating cardiac transcription factors and MAP kinase activation. Mol Biol Cell 17: 3978-3988, 2006.
76. Lin C, Rajakumar A, Plymire DA, Verma V, Markovic N, Hubel CA. Maternal endothelial progenitor colony-forming units with macrophage characteristics are reduced in preeclampsia. Am J Hypertens 22: 1014-1019, 2009.
77. Loomans CJM, de Koning EJP, Staal FJT, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld A-J. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53: 195-199, 2004.
78. Luksha L, Luksha N, Kublickas M, Nisell H, Kublickiene K. Diverse mechanisms of endothelium-derived hyperpolarizing factor-mediated dilatation in small myometrial arteries in normal human pregnancy and preeclampsia. Biol Reprod 83: 728-735, 2010.
79. Luksha L, Nisell H, Luksha N, Kublickas M, Hultenby K, Kublickiene K. Endothelium-derived hyperpolarizing factor in preeclampsia: heterogeneous contribution, mechanisms, and morphological prerequisites. Am J Physiol Regul Integr Comp Physiol 294: R510-R519, 2008.
80. Luppi P, Powers RW, Verma V, Edmunds L, Plymire D, Hubel CA. Maternal circulating CD34+VEGFR-2+ and CD133+VEGFR-2+ progenitor cells increase during normal pregnancy but are reduced in women with preeclampsia. Reproductive Sciences 17: 643-652, 2010.
81. Luppi P, Tse H, Lain KY, Markovic N, Piganelli JD, DeLoia JA. Preeclampsia activates circulating immune cells with engagement of the NF-κB pathway. Am J Reprod Immunol 56: 135-144, 2006.
82. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol 262: C854-C861, 1992.
83. Matijevic R, Johnston T. In vivo assessment of failed trophoblastic invasion of the spiral arteries in pre-eclampsia. BJOG: An International Journal of Obstetrics & Gynaecology 106: 78-82, 1999.
84. Maynard SE, Min J-Y, Merchan J, Lim K-H, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658, 2003.
85. McCarthy AL, Woolfson RG, Raju SK, Poston L. Abnormal endothelial cell function of resistance arteries from women with preeclampsia. Am J Obstet Gynecol 168: 1323-1330, 1993.
86. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 156: 918-930, 2008.
87. McElrath TF, Lim K-H, Pare E, Rich-Edwards J, Pucci D, Troisi R, Parry S. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 207: 407.e1-407.e7, 2012.
88. McKeeman GC, Ardill JES, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 191: 1240-1246, 2004.
89. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. BJOG: An International Journal of Obstetrics & Gynaecology 101: 669-674, 1994.
90. Molvarec A, Ito M, Shima T, Yoneda S, Toldi G, Stenczer B, Vásárhelyi B, Rigó J Jr, Saito S. Decreased proportion of peripheral blood vascular endothelial growth factor-expressing T and natural killer cells in preeclampsia. Am J Obstet Gynecol 203: 567.e1-567.e8, 2010.
91. Morton JS, Abdalvand A, Jiang Y, Sawamura T, Uwiera RRE, Davidge ST. Lectin-like oxidized low-density lipoprotein 1 receptor in a reduced uteroplacental perfusion pressure rat model of preeclampsia. Hypertension 59: 1014-1020, 2012.
92. Murphy C, Kanaganayagam GS, Jiang B, Chowienczyk PJ, Zbinden R, Saha M, Rahman S, Shah AM, Marber MS, Kearney MT. Vascular dysfunction and reduced circulating endothelial progenitor cells in young healthy UK South Asian men. Arterioscler Thromb Vasc Biol 27: 936-942, 2007.
93. Murphy MSQ, Casselman RC, Smith GN. Postpartum alterations in circulating endothelial progenitor cells in women with a history of pre-eclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 3: 178-185, 2013.
94. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 75: 1-8, 2008.
95. Myers J, Mires G, Macleod M, Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension 45: 258-263, 2005.
96. Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, Momoeda M, Kozuma S, Taketani Y. Cytotrophoblasts up-regulate soluble fms-Like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145: 4838-4845, 2004.
97. Naicker T, Khedun SM, Moodley J, Pijnenborg R. Quantitative analysis of trophoblast invasion in preeclampsia. Acta Obstet Gynecol Scand 82: 722-729, 2003.
98. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 291: R1085-R1093, 2006.
99. Osol G, Celia G, Gokina N, Barron C, Chien E, Mandala M, Luksha L, Kublickiene K. Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am J Physiol Heart Circ Physiol 294: H1381-H1387, 2008.
100. Palmer SK, Zamudio S, Coffin C, Parker S, Stamm E, Moore LG. Quantitative estimation of human uterine artery blood flow and pelvic blood flow redistribution in pregnancy. Obstet Gynecol 80: 1000-1006, 1992.
101. Pan Q, Qiu W-Y, Huo Y-N, Yao Y-F, Lou MF. Low levels of hydrogen peroxide stimulate corneal epithelial cell adhesion, migration, and wound healing. Invest Ophthalmol Vis Sci 52: 1723-1734, 2011.
102. Parrish MR, Murphy SR, Rutland S, Wallace K, Wenzel K, Wallukat G, Keiser S, Ray LF, Dechend R, Martin JN, Granger JP, LaMarca B. The effect of immune factors, tumor necrosis factor-α, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens 23: 911-916, 2010.
103. Parrish MR, Ryan MJ, Glover P, Brewer J, Ray L, Dechend R, Martin JN Jr, Lamarca BB. Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction. Gend Med 8: 184-188, 2011.
104. Parrish MR, Wallace K, Tam Tam KB, Herse F, Weimer A, Wenzel K, Wallukat G, Ray LF, Arany M, Cockrell K, Martin JN, Dechend R, LaMarca B. Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension. Am J Hypertens 24: 835-840, 2011.
105. Pascoal IF, Lindheimer MD, Nalbantian-Brandt C, Umans JG. Preeclampsia selectively impairs endothelium-dependent relaxation and leads to oscillatory activity in small omental arteries. J Clin Invest 101: 464-470, 1998.
106. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 269: 6271-6274, 1994.
107. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 70: 427-451, 1990.
108. Pritchard JA. Changes in the blood volume during pregnancy and delivery. Anesthesiology 26: 393-399, 1965.
109. Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K, Levy AP, Levy NS, Goldberg MA, D'Amato RJ, Adamis AP. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 46: 1619-1626, 1997.
110. Ramirez RJJ, Debrah J, Novak J. Increased myogenic responses of resistance-sized mesenteric arteries after reduced uterine perfusion pressure in pregnant rats. Hypertens Pregnancy 30: 45-57, 2011.
111. Redman CWG, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180: 499-506, 1999.
112. Rega G, Kaun C, Demyanets S, Pfaffenberger S, Rychli K, Hohensinner PJ, Kastl SP, Speidl WS, Weiss TW, Breuss JM, Furnkranz A, Uhrin P, Zaujec J, Zilberfarb V, Frey M, Roehle R, Maurer G, Huber K, Wojta J. Vascular endothelial growth factor is induced by the inflammatory cytokines Interleukin-6 and oncostatin M in human adipose tissue in vitro and in murine adipose tissue in vivo. Arterioscler Thromb Vasc Biol 27: 1587-1595, 2007.
113. Reho JJ, Peck J, Novak J, Ramirez RJ. Hypertension induced by episodic reductions in uteroplacental blood flow in gravid rat. Hypertens Pregnancy 30: 208-220, 2011.
114. Reho JJ, Toot JD, Peck J, Novak J, Yun YH, Ramirez RJ. Increased myogenic reactivity of uterine arteries from pregnant rats with reduced uterine perfusion pressure. Pregnancy Hypertension 2: 106-114, 2012.
115. Rizos D, Eleftheriades M, Batakis E, Rizou M, Haliassos A, Hassiakos D, Botsis D. Levels of asymmetric dimethylarginine throughout normal pregnancy and in pregnancies complicated with preeclampsia or had a small for gestational age baby. J Matern Fetal Neonatal Med 25: 1311-1315, 2012.
116. Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 4: 700-708, 1991.
117. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 161: 1200-1204, 1989.
118. Roggensack AM, Zhang Y, Davidge ST. Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension 33: 83-89, 1999.
119. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine R, Karumanchi SA. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21: 9-23, 2008.
120. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y. The role of the immune system in preeclampsia. Mol Aspects Med 28: 192-209, 2007.
121. Saito S, Umekage H, Sakamoto Y, Sakai M, Tanebe K, Sasaki Y, Morikawa H. Increased T-Helper-1-type immunity and decreased T-Helper-2-type immunity in patients with preeclampsia. Am J Reprod Immunol 41: 297-306, 1999.
122. Sandrim VC, Palei ACT, Metzger IF, Gomes VA, Cavalli RC, Tanus-Santos JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 52: 402-407, 2008.
123. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med 8: 1-20, 2006.
124. Sankaralingam S, Xu H, Davidge ST. Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia. Cardiovasc Res 85: 194-203, 2010.
125. Sankaralingam S, Xu Y, Sawamura T, Davidge ST. Increased lectin-like oxidized low-density lipoprotein receptor-1 expression in the maternal vasculature of women with preeclampsia: role for peroxynitrite. Hypertension 53: 270-277, 2009.
126. Savvidou MD, Hingorani AD, Tsikas D, Frölich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 361: 1511-1517, 2003.
127. Shaarawy M, Didy HE. Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. Int J Gynecol Obstet 55: 135-139, 1996.
128. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
129. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 102: 181-192, 2003.
130. Sibai BM, Barton JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol 196: 514.e1-514.e9, 2007.
131. Sibai B, Dekker GA, Kupferminc M. Pre-eclampsia. Lancet 365: 785-799, 2005.
132. Sipos PI, Crocker IP, Hubel CA, Baker PN. Endothelial progenitor cells: their potential in the placental vasculature and related complications. Placenta 31: 1-10, 2010.
133. Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 376: 631-644, 2010.
134. St-Jacques S, Forte M, Lye SJ, Letarte M. Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod 51: 405-413, 1994.
135. Sugawara J, Mitsui-Saito M, Hayashi C, Hoshiai T, Senoo M, Chisaka H, Yaegashi N, Okamura K. Decrease and senescence of endothelial progenitor cells in patients with preeclampsia. J Clin Endocrinol Metab 90: 5329-5332, 2005.
136. Sugawara J, Mitsui-Saito M, Hoshiai T, Hayashi C, Kimura Y, Okamura K. Circulating endothelial progenitor cells during human pregnancy. J Clin Endocrinol Metab 90: 1845-1848, 2005.
137. Sugino N, Kashida S, Karube-Harada A, Takiguchi S, Kato H. Expression of vascular endothelial growth factor (VEGF) and its receptors in human endometrium throughout the menstrual cycle and in early pregnancy. Reproduction 123: 379-387, 2002.
138. Szarka A, Rigo J, Lazar L, Beko G, Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 11: 59, 2010.
139. Takata M, Nakatsuka M, Kudo T. Differential blood flow in uterine, ophthalmic, and brachial arteries of preeclamptic women. Obstet Gynecol 100: 931-939, 2002.
140. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 65: 550-563, 2005.
141. Taylor RN, Musci TJ, Rodgers GM, Roberts JM. Preeclamptic sera stimulate increased platelet-derived growth factor mRNA and protein expression by cultured human endothelial cells. Am J Reprod Immunol 25: 105-108, 1991.
142. VanWijk MJ, Svedas E, Boer K, Nieuwland R, VanBavel E, Kublickiene KR. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol 187: 1686-1693, 2002.
143. Var A, Yildirim Y, Onur E, Kuscu NK, Uyanik BS, Goktalay K, Guvenc Y. Endothelial dysfunction in preeclampsia: oncreased homocysteine and decreased nitric oxide levels. Gynecol Obstet Invest 56: 221-224, 2003.
144. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: e1-e7, 2001.
145. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12: 642-649, 2006.
146. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 103: 945-952, 1999.
147. Walsh SK, English FA, Crocker IP, Johns EJ, Kenny LC. Contribution of PARP to endothelial dysfunction and hypertension in a rat model of pre-eclampsia. Br J Pharmacol 166: 2109-2116, 2012.
148. Walsh SK, English FA, Johns EJ, Kenny LC. Plasma-mediated vascular dysfunction in the reduced uterine perfusion pressure model of preeclampsia: a microvascular characterization. Hypertension 54: 345-351, 2009.
149. Wang YP, Walsh SW, Guo JD, Zhang JY. The imbalance between thromboxane and prostacyclin in preeclampsia is associated with an imbalance between lipid peroxides and vitamin E in maternal blood. Am J Obstet Gynecol 165: 1695-1700, 1991.
150. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353: 999-1007, 2005.
151. Wheeler T, Evans PW, Anthony FW, Godfrey KM, Howe DT, Osmond C. Relationship between maternal serum vascular endothelial growth factor concentration in early pregnancy and fetal and placental growth. Hum Reprod 14: 1619-1623, 1999.
152. Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 420: 28-32, 1997.
153. Yang X, Wang F, Chang H, Zhang S, Yang L, Wang X, Cheng X, Zhang M, Ma XL, Liu H. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J Hypertens 26: 1629-1635, 2008. doi:10.1097/HJH.0b013e328304dbff.
154. Yoshizumi M, Perrella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 73: 205-209, 1993.
155. Zhou CC, Ahmad S, Mi T, Abbasi S, Xia L, Day M-C, Ramin SM, Ahmed A, Kellems RE, Xia Y. Autoantibody from women with preeclampsia induces soluble fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 51: 1010-1019, 2008.
156. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype: one cause of defective endovascular invasion in this syndrome? J Clin Invest 99: 2152-2164, 1997.